Fig. 3: Clinical, genomic, and tumorigenic comparisons of defined subtypes.
From: Multi-omics and pharmacological characterization of patient-derived glioma cell lines
a Kaplan–Meier survival curves for GBM patients from the TCGA cohort with different subtypes. The P-value was calculated using the log-rank test. b Response to radiotherapy for defined subtypes. The y-axis represents the percentage of surviving cells upon radiation. P-values were calculated using the two-sided Wilcoxon rank-sum exact test. Boxplots show the median (center line), the upper and lower quantiles (box), and the range of the data (whiskers). c Frequency of genomic alterations of the indicated genes in PDGCs of different subtypes. Bars were colored by alteration types. AMP: high-level amplification, GAIN: low-level gain, HETLOSS: heterozygous deletion, HOMDEL: homozygous deletion, MISSENSE: missense mutation, TRUNC: truncation mutation. d Stacked barplots showing the tumorigenicity of PDGCs of different subtypes. For each cell line, 5 × 105 cells were injected into the brains of nude mice. e 3D scatterplot showing the subtype score of PDGCs and their transplanted tumors’ cell culture. f Scatter plots showing the median survival time of nude mice after injection of PDGCs of different subtypes. MES (n = 2), PN (n = 6), OXPHOS (n = 8), other (n = 2). The lines were plotted as mean ± SEM. Source data are provided as a Source Data file.
